These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 34182538)

  • 1. GPR30-mediated HMGB1 upregulation in CAFs induces autophagy and tamoxifen resistance in ERα-positive breast cancer cells.
    Liu L; Liu S; Luo H; Chen C; Zhang X; He L; Tu G
    Aging (Albany NY); 2021 Jun; 13(12):16178-16197. PubMed ID: 34182538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer.
    Mo Z; Liu M; Yang F; Luo H; Li Z; Tu G; Yang G
    Breast Cancer Res; 2013 Nov; 15(6):R114. PubMed ID: 24289103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
    Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC
    Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GPER-mediated proliferation and estradiol production in breast cancer-associated fibroblasts.
    Luo H; Yang G; Yu T; Luo S; Wu C; Sun Y; Liu M; Tu G
    Endocr Relat Cancer; 2014 Apr; 21(2):355-69. PubMed ID: 24481325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamoxifen induces toxicity, causes autophagy, and partially reverses dexamethasone resistance in Jurkat T cells.
    Torres-López L; Maycotte P; Liñán-Rico A; Liñán-Rico L; Donis-Maturano L; Delgado-Enciso I; Meza-Robles C; Vásquez-Jiménez C; Hernández-Cruz A; Dobrovinskaya O
    J Leukoc Biol; 2019 May; 105(5):983-998. PubMed ID: 30645008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth.
    Catalano S; Giordano C; Panza S; Chemi F; Bonofiglio D; Lanzino M; Rizza P; Romeo F; Fuqua SA; Maggiolini M; Andò S; Barone I
    Breast Cancer Res Treat; 2014 Jul; 146(2):273-85. PubMed ID: 24928526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estradiol and tamoxifen induce cell migration through GPR30 and activation of focal adhesion kinase (FAK) in endometrial cancers with low or without nuclear estrogen receptor α (ERα).
    Tsai CL; Wu HM; Lin CY; Lin YJ; Chao A; Wang TH; Hsueh S; Lai CH; Wang HS
    PLoS One; 2013; 8(9):e72999. PubMed ID: 24039841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stabilization of MORC2 by estrogen and antiestrogens through GPER1- PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells.
    Yang F; Xie HY; Yang LF; Zhang L; Zhang FL; Liu HY; Li DQ; Shao ZM
    Autophagy; 2020 Jun; 16(6):1061-1076. PubMed ID: 32401166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells.
    Vivacqua A; Bonofiglio D; Recchia AG; Musti AM; Picard D; Andò S; Maggiolini M
    Mol Endocrinol; 2006 Mar; 20(3):631-46. PubMed ID: 16239258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1.
    Li Y; Birnbaumer L; Teng CT
    Mol Endocrinol; 2010 May; 24(5):969-80. PubMed ID: 20211987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSNK1G2 differently sensitizes tamoxifen-induced decrease in PI3K/AKT/mTOR/S6K and ERK signaling according to the estrogen receptor existence in breast cancer cells.
    Nguyen Hoang AT; Hoe KL; Lee SJ
    PLoS One; 2021; 16(4):e0246264. PubMed ID: 33861751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GPER promotes tamoxifen-resistance in ER+ breast cancer cells by reduced Bim proteins through MAPK/Erk-TRIM2 signaling axis.
    Yin H; Zhu Q; Liu M; Tu G; Li Q; Yuan J; Wen S; Yang G
    Int J Oncol; 2017 Oct; 51(4):1191-1198. PubMed ID: 28902352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferation.
    Moerkens M; Zhang Y; Wester L; van de Water B; Meerman JH
    BMC Cancer; 2014 Apr; 14():283. PubMed ID: 24758408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
    Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
    Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoplasmic GPER translocation in cancer-associated fibroblasts mediates cAMP/PKA/CREB/glycolytic axis to confer tumor cells with multidrug resistance.
    Yu T; Yang G; Hou Y; Tang X; Wu C; Wu XA; Guo L; Zhu Q; Luo H; Du YE; Wen S; Xu L; Yin J; Tu G; Liu M
    Oncogene; 2017 Apr; 36(15):2131-2145. PubMed ID: 27721408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silencing of MicroRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells.
    Yu X; Li R; Shi W; Jiang T; Wang Y; Li C; Qu X
    Biomed Pharmacother; 2016 Feb; 77():37-44. PubMed ID: 26796263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
    Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA
    Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells.
    Ignatov A; Ignatov T; Roessner A; Costa SD; Kalinski T
    Breast Cancer Res Treat; 2010 Aug; 123(1):87-96. PubMed ID: 19911269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.
    Gu W; Dong N; Wang P; Shi C; Yang J; Wang J
    Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.